A report recently published by Allied Market Research indicated that the global acne medication market size was US$11.86 billion in 2019, and is projected to reach US$13.35 billion by 2027.

(RTTNews) - Ascletis Pharma Inc. said that China National Medical Products Administration (NMPA) has approved the Phase II clinical trial application of ASC40 for the treatment of patients with ...

The Chinese Phase III study (NCT06192264), which was conducted by Ascletis, saw denifanstat achieve a 33.2% treatment success in patients with acne vulgaris taking the oral medication for 12 weeks.

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

As the clean beauty movement continues to gain momentum, more skincare brands are looking to traditional Chinese medicine (TCM) to source natural ingredients that are chemical-free and effective ...